Aptahem (APTA.ST) Stock Analysis & AI Equity Report
Aptahem (APTA.ST) overview
Aptahem (APTA.ST) stock analysis and AI equity research. For the latest completed financial year, 2024, Aptahem reported revenue of SEK 3.8m and operating profit of SEK -8.2m; the year-end share price was 1.42 SEK and market capitalisation was SEK 17.6m. Aptahem is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Aptahem's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2025-09-29. Data will be refreshed during report generation.
About Aptahem
Aptahem AB is a biotechnology company developing RNA-based, aptamer-derived medicines for acute, life-threatening inflammatory conditions. Its lead candidate, Apta-1, is being developed in early clinical phase for sepsis and related disorders involving coagulation, inflammation and tissue damage. The company also pursues patent protection and partnering opportunities to advance its pipeline.
Generate the Aptahem report
Aptahem is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Aptahem and represent the latest completed financial year (2024). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.